Lenalidomide in combination with R‐ESHAP in patients with relapsed or refractory diffuse large B‐cell lymphoma: A phase 2 study from GELTAMO
British Journal of Haematology · 2023
DOI: 10.1111/bjh.18989 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift British Journal of Haematology, 2023. Verfasst von A Martín García-Sancho und 16 weiteren Autor:innen. Beteiligte Einrichtung: Hematology Department, Hospital Universitario de Salamanca-IBSAL, CIBERONC, Universidad de Salamanca, Salamanca, Spain. Hauptthemen laut MEDLINE: Lymphoma, Non-Hodgkin, Lymphoma, Large B-Cell, Diffuse, Neutropenia, Thrombocytopenia. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 28 Literaturangaben. Gefördert von: Celgene.
Abstract (Originalsprache)
Diffuse large B‐cell lymphoma (DLBCL) patients with relapsed or refractory (RR) disease have poor outcomes with current salvage regimens. We conducted a phase 2 trial to analyse the safety and efficacy of adding lenalidomide to R‐ESHAP (LR‐ESHAP) in patients with RR DLBCL. Subjects received 3 cycles of lenalidomide 10 mg/day on days 1–14 of every 21‐day cycle, in combination with R‐ESHAP at standard doses. Responding patients underwent autologous stem‐cell transplantation (ASCT). The primary endpoint was the overall response rate (ORR) after 3 cycles. Centralized cell‐of‐origin (COO) classification was performed. Forty‐six patients were included. The ORR after LR‐ESHAP was 67% (35% of patients achieved complete remission). Patients with primary refractory disease ( n = 26) had significantly worse ORR than patients with non‐refractory disease (54% vs. 85%, p = 0.031). No differences in response rates according to the COO were observed. Twenty‐eight patients (61%) underwent ASCT. At a median follow‐up of 41 months, the estimated 3‐year PFS and OS were 42% and 48%, respectively. The most common grade ≥3 adverse events were thrombocytopenia (70% of patients), neutropenia (67%) and anaemia (35%). There were no treatment‐related deaths during LR‐ESHAP cycles. In conclusion, LR‐ESHAP is a feasible salvage regimen with promising efficacy results for patients with RR DLBCL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Hematology Department, Hospital Universitario de Salamanca-IBSAL, CIBERONC, Universidad de Salamanca, Salamanca, Spain.
- Hematology Department, Hospital Universitario Virgen del Rocío/Virgen Macarena, Sevilla, Spain.
- Hematology Department, Hospital Clinic, Barcelona, Spain.
- Hematology Department, Hospital Germans Trias i Pujol/ICO-IJC, Badalona, Spain.
- Hematology Department, Hospital Universitari i Plotècnic La Fe, CIBERONC, Valencia, Spain.
- Institut Català d'Oncologia-Hospitalet, IDIBELL, Universitat de-Barcelona, Barcelona, Spain.
ORCID-Profile: A Martín García-Sancho, I Dlouhy, J M Sancho, J Bergua, A López-Guillermo
Förderung
- Celgene
Zitieren
APA
Martín García-Sancho, A., Baile, M., Rodríguez, G., Dlouhy, I., Sancho, J. M., Jarque, I., González-Barca, E., Salar, A., Espeso, M., Grande, C., Bergua, J., Montes-Moreno, S., Redondo, A., Enjuanes, A., Campo, E., López-Guillermo, A., & Caballero, D. (2023). Lenalidomide in combination with R‐ESHAP in patients with relapsed or refractory diffuse large B‐cell lymphoma: A phase 2 study from GELTAMO. British Journal of Haematology. https://doi.org/10.1111/bjh.18989
Vancouver
Martín García-Sancho A, Baile M, Rodríguez G, Dlouhy I, Sancho JM, Jarque I, et al. Lenalidomide in combination with R‐ESHAP in patients with relapsed or refractory diffuse large B‐cell lymphoma: A phase 2 study from GELTAMO. British Journal of Haematology. 2023. doi:10.1111/bjh.18989
BibTeX
@article{MartnGarcaSancho2023,
author = {Martín García-Sancho, A and Baile, M and Rodríguez, G and Dlouhy, I and Sancho, J M and Jarque, I and González-Barca, E and Salar, A and Espeso, M and Grande, C and Bergua, J and Montes-Moreno, S and Redondo, A and Enjuanes, A and Campo, E and López-Guillermo, A and Caballero, D},
title = {Lenalidomide in combination with R‐ESHAP in patients with relapsed or refractory diffuse large B‐cell lymphoma: A phase 2 study from GELTAMO},
journal = {British Journal of Haematology},
year = {2023},
doi = {10.1111/bjh.18989}
}
EUVIMED